John E Janik
Overview
Explore the profile of John E Janik including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
3049
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Piotrowska Z, Tan D, Smit E, Spira A, Soo R, Nguyen D, et al.
J Clin Oncol
. 2023 Jun;
41(26):4218-4225.
PMID: 37384848
Purpose: Although several agents targeting epidermal growth factor receptor () exon 20 insertions (ex20ins) have recently been approved by the US Food and Drug Administration, toxicities related to the inhibition...
2.
Davis E, Martin-Liberal J, Kristeleit R, Cho D, Blagden S, Berthold D, et al.
J Immunother Cancer
. 2022 Oct;
10(10).
PMID: 36316061
Background: OX40 is a costimulatory receptor upregulated on antigen-activated T cells and constitutively expressed on regulatory T cells (Tregs). INCAGN01949, a fully human immunoglobulin G1κ anti-OX40 agonist monoclonal antibody, was...
3.
Moiseyenko A, Muggia F, Condamine T, Pulini J, Janik J, Cho D
Gynecol Oncol Rep
. 2020 Oct;
34:100655.
PMID: 33083509
Agonists of the co-stimulatory molecule OX40 (CD134) are in clinical assessment alone and in combination with other immunotherapies. Recent pre-clinical studies have suggested that concurrent administration of OX40 agonists with...
4.
Verma V, Shrimali R, Ahmad S, Dai W, Wang H, Lu S, et al.
Nat Immunol
. 2019 Sep;
20(11):1555.
PMID: 31551574
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
5.
Verma V, Shrimali R, Ahmad S, Dai W, Wang H, Lu S, et al.
Nat Immunol
. 2019 Jul;
20(9):1231-1243.
PMID: 31358999
Understanding resistance to antibody to programmed cell death protein 1 (PD-1; anti-PD-1) is crucial for the development of reversal strategies. In anti-PD-1-resistant models, simultaneous anti-PD-1 and vaccine therapy reversed resistance,...
6.
Nayak-Kapoor A, Hao Z, Sadek R, Dobbins R, Marshall L, Vahanian N, et al.
J Immunother Cancer
. 2018 Jun;
6(1):61.
PMID: 29921320
Background: Indoleamine-2,3-dioxygenase 1 (IDO1) catalyzes the oxidation of tryptophan into kynurenine and is partially responsible for acquired immune tolerance associated with cancer. The IDO1 small molecule inhibitor navoximod (GDC-0919, NLG-919)...
7.
Berrong Z, Mkrtichyan M, Ahmad S, Webb M, Mohamed E, Okoev G, et al.
Cancer Immunol Res
. 2018 Jan;
6(2):201-208.
PMID: 29305519
Although an immune response to tumors may be generated using vaccines, so far, this approach has only shown minimal clinical success. This is attributed to the tendency of cancer to...
8.
Shrimali R, Ahmad S, Verma V, Zeng P, Ananth S, Gaur P, et al.
Cancer Immunol Res
. 2017 Aug;
5(9):755-766.
PMID: 28848055
Combination therapies that depend on checkpoint inhibitor antibodies (Abs) such as for PD-1 or its ligand (PD-L1) together with immune stimulatory agonist Abs like anti-OX40 are being tested in the...
9.
Sharma K, Janik J, OMahony D, Stewart D, Pittaluga S, Stetler-Stevenson M, et al.
Clin Cancer Res
. 2016 Aug;
23(1):35-42.
PMID: 27486175
Purpose: Therapeutic regimens for adult T-cell leukemia/lymphoma (ATL) are limited with unsatisfactory results, thereby warranting development of novel therapies. This study investigated antitumor activity and toxicity of alemtuzumab with regard...
10.
Janik J, Morris J, OMahony D, Pittaluga S, Jaffe E, Redon C, et al.
Proc Natl Acad Sci U S A
. 2015 Oct;
112(42):13045-50.
PMID: 26438866
Despite significant advances in the treatment of Hodgkin's lymphoma (HL), a significant proportion of patients will not respond or will subsequently relapse. We identified CD25, the IL-2 receptor alpha subunit,...